205 related articles for article (PubMed ID: 29930010)
1. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Sakamoto Y; Ishida T; Masaki A; Murase T; Yonekura K; Tashiro Y; Tokunaga M; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Inagaki H
Blood; 2018 Aug; 132(7):758-761. PubMed ID: 29930010
[No Abstract] [Full Text] [Related]
2. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
5. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395
[TBL] [Abstract][Full Text] [Related]
8. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
[No Abstract] [Full Text] [Related]
9. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
10. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
11. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
[No Abstract] [Full Text] [Related]
12. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis.
Yoshida N; Miyoshi H; Kato T; Sakata-Yanagimoto M; Niino D; Taniguchi H; Moriuchi Y; Miyahara M; Kurita D; Sasaki Y; Shimono J; Kawamoto K; Utsunomiya A; Imaizumi Y; Seto M; Ohshima K
J Pathol; 2016 Apr; 238(5):621-6. PubMed ID: 26847489
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
Tokunaga M; Yonekura K; Nakamura D; Haraguchi K; Tabuchi T; Fujino S; Hayashida M; Maekawa K; Arai A; Nakano N; Kamada Y; Kubota A; Inoue H; Owatari S; Takeuchi S; Takatsuka Y; Otsuka M; Hanada S; Matsumoto T; Yoshimitsu M; Ishitsuka K; Utsunomiya A
Br J Haematol; 2018 May; 181(4):539-542. PubMed ID: 28369823
[No Abstract] [Full Text] [Related]
14. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
15. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
Haji S; Kiyasu J; Choi I; Suehiro Y; Toyoda K; Tsuda M; Takamatsu A; Nakashima Y; Miyoshi H; Shiratsuchi M; Yamasaki S; Uike N; Abe Y
Bone Marrow Transplant; 2016 Mar; 51(3):432-4. PubMed ID: 26524267
[No Abstract] [Full Text] [Related]
16. No effect of humanized CCR monoclonal antibody (mogamulizumab) on treatment-resistant adult T cell leukemia with meningeal infiltration.
Tsutsumi Y; Shimono J; Miyashita N; Teshima T
Leuk Lymphoma; 2014 Feb; 55(2):457-9. PubMed ID: 23697876
[No Abstract] [Full Text] [Related]
17. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
[TBL] [Abstract][Full Text] [Related]
19. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
20. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
